The pharmacoepidemiology of COPD: recent advances and methodological discussion

P Burney, S Suissa, J B Soriano, W M Vollmer, G Viegi, S D Sullivan, L M Fabbri, D D Sin, P Ernst, D Coultas, J Bourbeau, D W Mapel, K Weiss, T McLaughlin, David Brendan Price, M C J M Sturkenboom, R Taylor, G W Hagan

Research output: Contribution to journalArticle

39 Citations (Scopus)
Original languageEnglish
Pages (from-to)1s-44s
Number of pages44
JournalEuropean Respiratory Journal
Volume43
Publication statusPublished - 1 Sep 2003

Keywords

  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Cost-Benefit Analysis
  • Europe
  • Female
  • Forecasting
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Pharmacoepidemiology
  • Pulmonary Disease, Chronic Obstructive
  • Quality of Life
  • Respiratory Function Tests
  • Risk Assessment
  • Severity of Illness Index
  • Sex Distribution
  • Survival Analysis
  • United States

Cite this

Burney, P., Suissa, S., Soriano, J. B., Vollmer, W. M., Viegi, G., Sullivan, S. D., Fabbri, L. M., Sin, D. D., Ernst, P., Coultas, D., Bourbeau, J., Mapel, D. W., Weiss, K., McLaughlin, T., Price, D. B., Sturkenboom, M. C. J. M., Taylor, R., & Hagan, G. W. (2003). The pharmacoepidemiology of COPD: recent advances and methodological discussion. European Respiratory Journal, 43, 1s-44s.